AIMS: Regulator of G protein signalling (RGS) proteins act as molecular 'off switches' that terminate G protein signalling by catalyzing the hydrolysis of Gα-bound GTP to GDP. Many different Gα(i)-coupled receptors have been implicated in the cardioprotective effects of ischaemic preconditioning. However, the role of RGS proteins in modulating cardioprotection has not been previously investigated. We used mice that were homozygous (GS/GS) or heterozygous (GS/+) for a mutation in Gα(i2) rendering it RGS-insensitive (G184S) to determine whether interactions between endogenous RGS proteins and Gα(i2) modulate Gα(i)-mediated protection from ischaemic injury. METHODS AND RESULTS: Langendorff-perfused mouse hearts were subjected to 30 min global ischaemia and 2 h reperfusion. Infarcts in GS/GS (14.5% of area at risk) and GS/+ (22.6% of AAR) hearts were significantly smaller than those of +/+ hearts (37.2% of AAR) and recovery of contractile function was significantly enhanced in GS/GS and GS/+ hearts compared with +/+ hearts. The cardioprotective phenotype was not reversed by wortmannin or U0126 but was reversed by 5-hydroxydecanoic acid and HMR 1098, indicating that RGS-insensitive Gα(i2) protects the heart through a mechanism that requires functional ATP-dependent potassium channels but does not require acute activation of extracellular-regulated kinase or Akt signalling pathways. CONCLUSIONS: This is the first study to demonstrate that Gα(i2)-mediated cardioprotection is suppressed by RGS proteins. These data suggest that RGS proteins may provide novel therapeutic targets to protect the heart from ischaemic injury.
AIMS: Regulator of G protein signalling (RGS) proteins act as molecular 'off switches' that terminate G protein signalling by catalyzing the hydrolysis of Gα-bound GTP to GDP. Many different Gα(i)-coupled receptors have been implicated in the cardioprotective effects of ischaemic preconditioning. However, the role of RGS proteins in modulating cardioprotection has not been previously investigated. We used mice that were homozygous (GS/GS) or heterozygous (GS/+) for a mutation in Gα(i2) rendering it RGS-insensitive (G184S) to determine whether interactions between endogenous RGS proteins and Gα(i2) modulate Gα(i)-mediated protection from ischaemic injury. METHODS AND RESULTS: Langendorff-perfused mouse hearts were subjected to 30 min global ischaemia and 2 h reperfusion. Infarcts in GS/GS (14.5% of area at risk) and GS/+ (22.6% of AAR) hearts were significantly smaller than those of +/+ hearts (37.2% of AAR) and recovery of contractile function was significantly enhanced in GS/GS and GS/+ hearts compared with +/+ hearts. The cardioprotective phenotype was not reversed by wortmannin or U0126 but was reversed by 5-hydroxydecanoic acid and HMR 1098, indicating that RGS-insensitive Gα(i2) protects the heart through a mechanism that requires functional ATP-dependent potassium channels but does not require acute activation of extracellular-regulated kinase or Akt signalling pathways. CONCLUSIONS: This is the first study to demonstrate that Gα(i2)-mediated cardioprotection is suppressed by RGS proteins. These data suggest that RGS proteins may provide novel therapeutic targets to protect the heart from ischaemic injury.
Authors: Levi L Blazer; David L Roman; Alfred Chung; Martha J Larsen; Benjamin M Greedy; Stephen M Husbands; Richard R Neubig Journal: Mol Pharmacol Date: 2010-06-22 Impact factor: 4.436
Authors: M Kume; Y Yamamoto; S Saad; T Gomi; S Kimoto; T Shimabukuro; T Yagi; M Nakagami; Y Takada; T Morimoto; Y Yamaoka Journal: J Lab Clin Med Date: 1996-09
Authors: Kuljeet Kaur; Sergio Parra; Rong Chen; Raelene A Charbeneau; Susan M Wade; Patrick Y Jay; Richard R Neubig Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-03-14 Impact factor: 3.000
Authors: Boyd R Rorabaugh; Bandana Chakravarti; Nathaniel W Mabe; Sarah L Seeley; Albert D Bui; Jianqi Yang; Stephanie W Watts; Richard R Neubig; Rory A Fisher Journal: J Pharmacol Exp Ther Date: 2016-12-29 Impact factor: 4.030
Authors: Ricardo O S Soares; Daniele M Losada; Maria C Jordani; Paulo Évora; Orlando Castro-E-Silva Journal: Int J Mol Sci Date: 2019-10-11 Impact factor: 5.923
Authors: Sergio Parra; Xinyan Huang; Raelene A Charbeneau; Susan M Wade; Kuljeet Kaur; Boyd R Rorabaugh; Richard R Neubig Journal: BMC Pharmacol Toxicol Date: 2014-06-05 Impact factor: 2.483
Authors: Caroline Bull Melsom; Øivind Ørstavik; Jan-Bjørn Osnes; Tor Skomedal; Finn Olav Levy; Kurt Allen Krobert Journal: PLoS One Date: 2014-09-09 Impact factor: 3.240